These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 31514735)

  • 1. Case report of rhabdomyosarcomatous transformation of a primary gastrointestinal stromal tumor (GIST).
    Li L; Khalili M; Johannes G; Baratam P; Morano WF; Styler M; Bowne WB; Hou JS
    BMC Cancer; 2019 Sep; 19(1):913. PubMed ID: 31514735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
    Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
    Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
    Tang M; Li DQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
    Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
    Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The diagnostic and predictive role of kit (CD117)].
    Dirnhofer S; Zimpfer A; Went P
    Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA involvement in gastrointestinal stromal tumor tumorigenesis.
    Kim WK; Yang HK; Kim H
    Curr Pharm Des; 2013; 19(7):1227-35. PubMed ID: 23092343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [To improve the understanding of CD117-negative gastrointestinal stromal tumor].
    Zhao Q; Li J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):831-834. PubMed ID: 31550821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST.
    Belinsky MG; Cai KQ; Zhou Y; Luo B; Pei J; Rink L; von Mehren M
    BMC Cancer; 2017 Aug; 17(1):512. PubMed ID: 28768491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.
    Dermawan JK; Vanderbilt CM; Chang JC; Untch BR; Singer S; Chi P; Tap WD; Antonescu CR
    Genes Chromosomes Cancer; 2022 Jul; 61(7):412-419. PubMed ID: 35170141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment: A case report and diagnostic utility of ETV1 mRNA in situ hybridization.
    Jung M; Park SH; Jeon YK; Won JK; Yang HK; Kim WH
    Medicine (Baltimore); 2017 Dec; 96(49):e9031. PubMed ID: 29245294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms of primary and secondary resistance, molecular-genetic features and characteristics of KIT/PDGFRA non-mutated GISTs].
    Kalfusová A; Kodet R
    Cesk Patol; 2017; 53(4):167-173. PubMed ID: 29227120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.